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Background: This study aimed to improve physicians’ understanding of the treatment 
  circumstances and needs of outpatients with schizophrenia at risk of nonadherence, by natural-
istically assessing antipsychotic treatment patterns, clinical outcomes, and health care service 
use in this little-studied patient population.
Methods: In this one-year, prospective, multicenter, noninterventional, observational study, 
patients considered at risk of nonadherence by their physicians were switched from their primary 
oral antipsychotic to another oral or a depot antipsychotic at study entry. All cause treatment 
discontinuation (antipsychotic switch, augmentation, or discontinuation) during the study was 
assessed using Kaplan–Meier survival analyses and descriptive statistics. Patients’ illness   severity, 
quality of life, attitude towards medication, patient-reported adherence, and health care resource 
utilization were assessed during the study.
Results: Of the 406 enrolled patients, 43 (10.6%) were switched to depot and 363 (89.4%) 
were switched to oral antipsychotics at study entry. During the study, 99 (24.4%) patients 
switched, augmented, or discontinued their antipsychotic (all cause treatment discontinuation). 
Of the 99 patients who switched, augmented, or discontinued their antipsychotic, 8 (18.6%) 
were taking depot and 91 (25.0%) were taking oral antipsychotics. These patients were switched 
to either depot (n = 15) or oral (n = 78) antipsychotics, or discontinued their antipsychotic 
medication (n = 6). Inadequate response was the most frequently reported reason for medication 
discontinuation. During the study, patients’ clinical and functional status improved significantly 
and service use was low. Most patients considered themselves to be adherent at study entry, 
and this favorable self-perception increased during the study (from 68.5% to 88.1%).
Conclusion: Although identified as at risk of nonadherence, few patients in this naturalistic 
study discontinued their prescribed antipsychotic medication during the study. The discrepancy 
between the physicians’ perception of their patient’s medication adherence and the patients’ 
self-perceived adherence highlights the need to better understand the underlying reasons for 
this phenomenon.
Keywords: antipsychotic drugs, medication persistence, outpatients, schizophrenia, depot 
antipsychotic, nonadherence
Background
Maintenance therapy with antipsychotic medication is necessary for the long-term 
clinical management of schizophrenia and is a key determinant for good prognosis.1 
Patients who discontinue their antipsychotic medication regimen do so for many 
reasons, such as insufficient efficacy or tolerability,2,3 and are at increased risk 
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  functional outcomes.8,9  Maintenance  therapy  with 
  antipsychotic medication is also compromised by patient 
nonadherence, a common challenge for physicians treating 
patients with schizophrenia in outpatient settings. At some 
point during their illness, up to 80% of patients will not 
fully adhere to their medication,10 and those who do not 
take their medication as prescribed are at an increased risk 
of relapse.11
Time to all cause treatment discontinuation has been 
used in recent studies as a clinically meaningful composite 
measure of treatment efficacy, tolerability, and safety as 
perceived by the physician and patient.3,12 Most studies 
assessing time to all cause treatment discontinuation found 
that the choice of antipsychotic medication influenced the 
time to and rates of treatment discontinuation.2,3,8,13–18 
Another potential factor that may influence treatment 
  discontinuation is a patient’s inherent risk of nonadherence. 
Nonadherence to antipsychotic medication in the previous 
six months was found to be the best single predictor of future 
nonadherence.19 However, few studies have assessed 
whether patients with schizophrenia who have been identi-
fied as being at risk of nonadherence (ie, do not regularly 
take their medication) are at increased risk of discontinuing 
their medication.
To the authors’ knowledge, this is the first study to 
prospectively assess antipsychotic medication discontinu-
ation over 12 months in outpatients with schizophrenia 
who were considered to be at risk of nonadherence by their 
physician. Patients were considered to be at risk of nonad-
herence according to one of five reasons: 1) insufficient 
efficacy,3 2) concerns around tolerability of the medication,3 
3)   history of medication nonadherence,19,20 4) poor insight 
into having a mental illness,20 or 5) negative attitude to 
their   medication.20 As this patient population had not been 
previously studied, the authors aimed to gather naturalistic, 
observational data to improve physicians’ understanding 
of this patient segment, their clinical circumstances, and 
their treatment needs.
The primary objective of this study was to assess the time 
to all cause treatment discontinuation (defined as any antip-
sychotic medication switch, augmentation, or discontinua-
tion). The secondary aims of this study were to report the   
antipsychotic usage patterns; the reasons for antipsychotic   
discontinuation and the time to treatment discontinuation for 
each of the main reasons; the change in patients’ illness 
severity, quality of life, and attitude towards their medication; 
and concomitant medication use, patient-reported adherence, 
and resource utilization.
Methods
study design
This was a one-year, prospective, multicenter, noninterven-
tional, observational study of outpatients with schizophrenia 
who required a change in their primary antipsychotic medica-
tion because of a physician-perceived risk of nonadherence. 
The study was conducted from April 2007 to July 2009 in 31 
clinical practice sites located in Australia (10), Mexico (3), 
Romania (14), and Taiwan (4).
All patients provided voluntary, written informed consent 
for the use of their personal health information collected in 
the study. The study was conducted in accordance with the 
Declaration of Helsinki and the applicable laws and regula-
tions of the study countries and regions, and was confirmed 
to be noninterventional by ethical review boards in each study 
country and region.
study population
The study population has been described previously.21 
In brief, male or female outpatients meeting diagnostic cri-
teria for schizophrenia (DSM-IV or DSM-IV TR)22 were 
included in this study if they: 1) were aged between 18 and 
65 years; 2) had at least two previous episodes of clinical 
worsening requiring hospitalization or increased level of care 
in the 24 months before study entry; 3) were considered at 
risk of nonadherence (lack of insight, negative drug attitude, 
documented history of medication nonadherence, inadequate 
response to the primary antipsychotic medication, or intoler-
ance to the primary antipsychotic medication) by their 
  physician; and 4) required a switch of their primary oral 
antipsychotic medication. Patients were excluded if they 
were considered by their physician to be treatment-resistant, 
or were receiving clozapine because of treatment resistance 
at study screening; were pregnant or nursing; or had an acute, 
serious, or unstable medical condition.
Treatment
All aspects of treatment and care of patients were determined 
by the treating physicians in keeping with their best clinical 
judgment. Treatment decisions were solely at the discretion 
of the physician and the patient, and treatment was prescribed 
according to the usual standard of care.
Enrolled patients were switched from their primary oral 
antipsychotic medication to another oral or a depot antipsy-
chotic up to 90 days before study entry (Day 0). At the physi-
cian’s discretion, the patient’s antipsychotic prescribed at 
study entry could be switched, augmented, or discontinued 
during the study for any reason. Medication switches or Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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augmentations included a switch to another antipsychotic, 
a change in antipsychotic formulation, or the addition 
of another antipsychotic. However, the addition of an oral 
antipsychotic to a depot antipsychotic or the discontinuation 
of an oral antipsychotic while taking a depot antipsychotic 
were not considered to be medication changes. Physicians 
selected reason(s) for any switch, augmentation, or discon-
tinuation of antipsychotic from the following: poor   
insight, negative drug attitude, inadequate response, lack of 
compliance (related to a documented history of nonadher-
ence), patient’s request, investigator decision, clinical 
relapse, intolerance to drug, prescription inconvenience, 
social reasons, and financial cost of medication. Physicians’ 
nominated the primary reason for any switch, augmentation, 
or discontinuation of antipsychotic if more than one reason 
was selected.
Patient assessment
Patients were observed for up to 12 months following enroll-
ment, and were assessed at Day 0 (study entry), Month 3 
(Visit 2), Month 12 (Visit 3), if they relapsed or withdrew 
from the study, and if they switched, augmented, or discon-
tinued their antipsychotic between study visits. Patient 
sociodemographic characteristics were recorded at study 
entry, and patient-reported medication adherence and 
resource utilization (number of and reasons for hospital 
admissions, number of outpatient visits to any physician 
including psychiatrists and physicians other than psychia-
trists, number of days in partial care, and number of emer-
gency room or equivalent visits [overnight stay] for 
psychiatric illness and nonpsychiatric illness) were recorded 
at all visits. At study entry, patients also reported on their 
alcohol consumption, smoking, and illicit drug use for the 
six months prior to study entry. Detailed information regard-
ing patient consumption habits and other sociodemographic 
characteristics have been published previously.21
Illness severity, assessed by the physician using the   
Clinical Global Impressions of Severity scale (CGI-S; 1 is 
not ill, 7 is extremely ill),23 and patient’s attitude to their 
medication(s), assessed using the self-report, 10-item Drug 
Attitude Inventory questionnaire (DAI-10; -10 is negative 
attitude, 10 is positive attitude),24 were recorded at all visits. 
Quality of life was assessed using the self-report European 
Quality of Life instrument (EuroQoL EQ-5D) at study entry 
and Month 12,25 whereas health-related quality of life was 
assessed using the patient-rated, 12-item Short-Form health 
survey (SF-12; 100 is best imaginable health state) at all 
visits.26 United Kingdom adult population-based preferences 
for the EQ-5D health states (100 is best imaginable health 
state) were used to calculate the EQ-5D utility score (1 is 
perfect health).27 The safety and tolerability data will be 
reported in a following publication of the study data.
statistical analysis
All patients who provided consent to release information, and 
who fulfilled the study entry criteria were included in the 
analyses. The analyses included data, up to the point of last 
data collection, for patients who were lost to follow-up or 
who dropped out of the study. Descriptive statistics were used 
to calculate the mean and standard deviation (SD) or the 
median, minimum (min), and maximum (max) for continuous 
variables, and counts and percentages for categorical vari-
ables. The mean ± SD dosage of each antipsychotic prescribed 
at study entry was calculated taking into account the days on 
therapy until treatment or study discontinuation. Statistical 
significance was prespecified at a two-sided P , 0.05. 
  Statistical Analysis Software (SAS; v 9.1.3, SAS Institute, 
Inc, Cary, NC) was used for all statistical analyses.
survival analysis
Survival analyses were conducted for time to all cause treat-
ment discontinuation. All cause treatment discontinuation 
was defined as any switch, augmentation, or discontinuation 
of antipsychotic medication for any reason. Patients who 
discontinued the study for any reason were assumed to be 
still taking their medication. Time to discontinuation was 
calculated from the date of study entry to the date of the first 
all cause treatment discontinuation. Survival curves were 
constructed using unadjusted Kaplan–Meier estimates. 
If appropriate, the median survival time estimates and 95% 
confidence intervals (CI) are presented. For the survival 
analyses, patients were censored if they discontinued from 
study for any reason, eg, death, lost to follow-up, or patient 
decision. The analysis was truncated at 365 days so that all 
patients had exactly 1-year of follow up.
change in clinical and functional status analyses
Analyses of the CGI-S, DAI-10, and EQ-5D scores excluded 
patients who switched antipsychotics more than seven days 
before their first study visit and analyses of SF-12 scores 
excluded patients who switched antipsychotics more than 
28 days before their first study visit to provide a more accurate 
representation of patient’s clinical and functional illness 
profile at study entry. The temporal changes in CGI-S and 
SF-12 scores were analyzed using mixed model repeated 
measures (MMRM) and in EQ-5D scores were analyzed Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
216
Kelin et al
using analysis of covariance (ANCOVA). Both the MMRM 
and ANCOVA were controlled for sociodemographics 
(age, gender, income status, marital status, smoking status, 
work status, and alcohol consumption during the six months 
before study entry) and baseline clinical characteristics (age 
at first episode, number of previous episodes or exacerbations 
of schizophrenia in the previous 24 months, duration of cur-
rent episode of schizophrenia, hospitalization in the six 
months before study entry, concomitant use of anticholin-
ergics at study entry, concomitant use of benzodiazepines at 
study entry, previous use of antidepressants, previous use of 
anxiolytics, sedatives, or hypnotics, previous use of mood 
stabilizers, body mass index [BMI], CGI-S score, EQ-5D 
health state score, EQ-5D utility score, SF-12 mental health 
score, and SF-12 physical component score). Measures of 
significance were based on the least square (LS) mean dif-
ference and type III sum-of-squares using a two-sided 
α = 0.05. The unstructured covariance structure was pre-
specified to model the within-patient errors. Only visits that 
were completed within the acceptable time frame for the 
visit were included.
Treatment response and relapse analyses
Patients were classified as responders if their CGI-S score 
decreased by $2 points from a score of $4 (moderately to 
extremely ill) at study entry, or by $1 point(s) from a score 
of 3 (mildly ill) at study entry. Patients with a CGI-S score 
of 1 or 2 were excluded from this analysis, and patients who 
responded and then relapsed were eligible to be classified as 
a responder after changing antipsychotic medication. Patients 
were classified as relapsed if they were classified as respond-
ers and their CGI-S score increased to that recorded at study 
entry or higher, and/or by $2 points from the lowest CGI-S 
score recorded at the previous visit.
Results
Patient disposition
Figure 1 provides an overview of patient disposition at study 
entry, which has previously been reported in detail.21 Of the 
440 patients considered to be at risk of nonadherence and who 
entered the study, 406 patients were enrolled (Australia, n = 64; 
Mexico, n = 40; Romania, n = 156; Taiwan, n = 146). The 
remaining 34 patients were excluded because of no data entry 
(n = 4), no antipsychotic change (n = 22), or an antipsychotic 
switch more than 90 days before study entry (n = 8).
Of the 406 enrolled patients, 318 (78.3%) completed 
the study. Fewer patients in Australia (71.9%, 46/64) and 
Taiwan (63.0%, 92/146) completed the study than patients 
in Mexico (92.5%, 37/40) and Romania (91.7%, 143/156). 
Patients (n = 88) who discontinued from the study did so 
because of: lost to follow up (58.0%, 51/88), subject deci-
sion (8.0%, 7/88), investigator decision (1.1%, 1/88), par-
ent/caregiver decision (1.1%, 1/88), clinical relapse (1.1%, 
1/88), or other reasons that were not reported (30.7%, 
27/88).
Patient sociodemographic characteristics
Patient sociodemographic characteristics at study entry 
have been reported in detail.21 Patients were in their late 
30s (mean ± SD, 37.2 ± 10.2 years), mostly male (56.7%, 
230/406), and had a mean ± SD BMI of 26.1 ± 5.56 kg/m2. 
At study entry, most patients reported that they had never 
Patients with schizophrenia
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No change in treatment,
n = 22
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married or had no previous or current relationship 
(59.6%, 242/406), lived with their family (82.0%, 333/406), 
were unemployed (43.4%, 176/406), and had no income 
(including pensions and allowances; 54.6%, 223/406). 
In the six months before study entry, 25.9% (105/406) of 
patients reported they had consumed alcohol and 6.2% 
(25/406) reported they had taken illicit drugs.
reasons for risk of nonadherence  
at study entry
Of the 406 enrolled patients, 224 (55.2%) were considered 
to be at risk of nonadherence by their physician because of 
an inadequate response to the primary antipsychotic 
medication. Of the remaining patients, 73 (18.0%) were 
considered at risk of nonadherence because of a negative 
drug attitude, 71 (17.5%) because of intolerance to the 
primary antipsychotic medication, 31 (7.6%) because of a 
documented history of medication nonadherence, and 
7 (1.7%) because of a lack of insight.
Antipsychotic switch patterns  
at study entry
Patients were switched from their primary oral antipsychotic 
medication to another oral antipsychotic (89.4%, 363/406) 
or a depot antipsychotic (10.6%, 43/406) within 90 days of 
study entry (Table 1). Most patients (84.5%, 343/406) had 
switched antipsychotics within seven days of study entry. 
Patients switched to depot antipsychotics were switched to 
either first-generation (48.8%, 21/43) or second-generation 
(51.2%, 22/43) depot antipsychotics. Zuclopenthixol decano-
ate (n = 8), haloperidol decanoate (n = 5), and pipotiazine 
palmitate (n = 5) were the most frequently prescribed first-
generation depot antipsychotics, whereas risperidone long-
acting injection (n =  22)  was  the  only  prescribed 
second-generation depot antipsychotic. The mean ± SD 
dosage of these antipsychotics was 314.1 ± 217.4 mg/month 
for zuclopenthixol, 73.4 ± 25.3 mg/month for haloperidol, 
92.0 ± 34.6 mg/month for pipotiazine, and 72.6 ± 25.7 mg/month 
for risperidone. Patients switched to oral antipsychotics were 
mostly switched to second-generation (89.5%, 325/363) 
rather than first-generation (10.5%, 38/363) agents. 
  Olanzapine (n = 93), amisulpride (n = 55), risperidone 
(n = 48), and aripiprazole (n = 47) were the most frequently 
prescribed second-generation oral antipsychotics, and halo-
peridol (n = 10) and trifluoperazine (n = 10) were the most 
frequently prescribed first-generation oral antipsychotics. 
The mean ± SD dosage of these antipsychotics was 
13.6 ± 8.39 mg/day for olanzapine, 609.1 ± 536.4 mg/day 
for amisulpride, 15.81 ± 9.67 mg/day for aripiprazole, 
3.89 ± 2.41 mg/day for risperidone, 5.54 ± 2.21 mg/day for 
haloperidol, and 9.65 ± 4.86 mg/day for trifluoperazine.
Time to treatment discontinuation
Of the 406 patients enrolled in the study, 99 (24.4%) 
switched, augmented, or discontinued their antipsychotic 
medication during the 12-month study period (all cause 
treatment discontinuation). As the proportion of patients 
who switched, augmented, or discontinued their medication 
did not reach 50% during the study, the median survival 
time for all cause treatment discontinuation could not be 
estimated from the Kaplan–Meier survival analysis 
(  Figure 2).   However, the 25th percentile (95% CI) 
  Kaplan–Meier estimate could be estimated at 310 (208, not 
  applicable) days for all cause treatment discontinuation. 
Table 1 Antipsychotic switch patterns at study entry 
Antipsychotic class n (%)
Depot 40 (9.9)
First-generation 20 (4.9)
second-generation 20 (4.9)
Depot + oral 3 (0.7)
First-generation + first-generation 1 (0.2)
second-generation + second-generation 2 (0.5)
Oral 362 (89.2)
First-generation 38 (9.4)
second-generation 324 (79.8)
Oral + oral 1 (0.2)
second-generation + first-generation 1 (0.2)
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Figure 2 Twelve-month Kaplan–Meier survival curve (n = 406) for all cause treatment 
discontinuation (event, n = 99; censored, n = 307). Time to discontinuation was 
calculated from the date of study entry to the date of the first all cause treatment 
discontinuation. For the survival analyses, patients were censored if they had not 
switched, augmented, or discontinued their antipsychotic medication at 365 days, if   
they had completed the study, or if they discontinued from the study for any reason. 
censored patients are denoted by . Median Kaplan–Meier estimates could not be 
calculated because the proportion of patients who had changed their medication 
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In lieu of median   Kaplan–Meier estimates, the median 
time to treatment   discontinuation was summarized using 
descriptive statistics as 102 (2, 365) days (n = 99). 
  Inadequate response (35.9%) was the most frequently 
reported reason for treatment   discontinuation (Table 2). 
Other frequently reported reasons were lack of compliance 
(14.1%), investigator decision (13.0%), and upon patient’s 
request (10.9%).
Antipsychotic medication use patterns
During the study, 8 (18.6%) patients in the depot subgroup 
and 91 (25.0%) patients in the oral subgroup switched, 
  augmented, or discontinued their medication at least once 
(all cause treatment discontinuation, Table 3). Most of these 
patients (93.9%, 93/99) switched or augmented their 
  medication; 15 patients were switched to depot antipsychotics 
and 78 patients were switched to oral antipsychotics. Most 
patients switched to depot antipsychotics were previously 
taking an oral antipsychotic (80.0%, 12/15). The remaining 
six patients, who were all taking oral antipsychotics, 
  discontinued their medication.
A small number of patients had more than one antipsy-
chotic medication switch or augmentation during the study. 
A further 26 patients (oral, n = 22; depot, n = 4) required a 
second switch or augmentation of their medication, and 
3 patients (oral, n = 3) discontinued their medication after 
one previous switch in their medication. In addition, 
8 patients (oral, n = 7; depot, n = 1) required a third, 2 patients 
(oral, n = 2) required a fourth, and 2 patients (oral, n = 2) 
required a fifth switch or augmentation of their medication. 
When study discontinuation was considered in addition to 
all cause treatment discontinuation, 66 patients (oral, n = 60; 
depot, n = 6) had not switched, augmented, or discontinued 
their medication before discontinuing the study, 8 patients 
(oral, n = 8) had switched, augmented, or discontinued their 
medication once before discontinuing the study, and 1 patient 
(oral, n = 1) had switched, augmented, or discontinued his/her 
medication twice before discontinuing the study.
Treatment response and relapse
Of those patients who had a CGI-S score .2 at study entry, 
22.5% (72/320) had responded to treatment at 3 months and 
41.5% (132/318) had responded at 12 months. However, 
13.7% (10/73) of responders had relapsed by 12 months.
change in clinical and functional status
Statistically significant changes in the overall patient popula-
tion’s CGI-S, DAI-10, EQ-5D, and SF-12 scores from study 
entry to 12 months or endpoint were detected (Table 4). On 
average, patients’ illness severity (CGI-S score) was classi-
fied as moderately ill at study entry and mildly ill by 
12 months (MMRM of the LS mean change, P , 0.001). 
Patients’ attitude to their antipsychotic medication 
(DAI-10 score) changed from slightly positive at study entry 
and slightly more positive by 12 months or endpoint. 
In   addition, patients rated their quality of life and level of 
functioning (EQ-5D and SF-12 scores) as low at study entry 
and higher by 12 months or endpoint (EQ-5D health state 
and utility scores, ANCOVA LS mean change, P , 0.001; 
SF-12 mental health and physical component scores, MMRM 
analysis LS mean change, P , 0.001).
concomitant medication use
Most patients (78.9%, 311/394) took concomitant medica-
tion for schizophrenia during the study. Benzodiazepines 
or anticholinergics (58.0%, 235/405) were the most com-
mon concomitant medication taken, followed by   anxiolytics, 
sedatives, or hypnotics (32.4%, 117/362), mood stabilizers 
(28.7%, 104/362), and antidepressants (27.1%, 97/358). In 
addition, most patients (77.9%, 307/394) took other psy-
chiatric medications, whereas few patients (13.1%, 46/352) 
had received nonpharmacological interventions during 
the study.
Patient-reported adherence
The percentage of patients who considered themselves to 
be adherent increased during the study. At study entry, 
68.5% (278/406) of patients considered themselves to have 
been adherent (they took all their medication or only missed 
taking their medication a couple of times) in the previous 
four weeks. In contrast, 86.8% (335/386) of patients at 
Table 2 reasons for all cause treatment discontinuation
Primary reason n (%)a Time (days) to treatment  
discontinuation for each  
reason, median (min, max)b
negative drug attitude 8 (8.7) nc
inadequate response 33 (35.9) 107 (2, 343)
Lack of compliance 13 (14.1) 135 (7, 364)
Upon patients’ request 10 (10.9) 101.5 (7, 200)
investigator decision 12 (13.0) 91.5 (8, 300)
clinical relapse 7 (7.6) nc
intolerance to drug 9 (9.8) nc
Notes: aFor the calculation of percentages, the denominator was n = 92; bTime to 
treatment discontinuation for each primary reason was estimated using data from 
patients who switched, augmented, or discontinued their antipsychotic medication for 
that reason only. Time to treatment discontinuation was not estimated for reasons 
with event numbers ,10.
Abbreviations: max, maximum; min, minimum; nc, not calculated.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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3 months and 88.1% (304/345) of patients at 12 months 
considered themselves to have been adherent since their last 
study visit.
resource utilization
During the study, 56 (16.7%) patients had at least one psy-
chiatric hospitalization. Of these patients, 39 (69.6%) had 
one, 10 had two (17.9%), and 7 (12.5%) had three hospital 
admissions. Of the remaining two patients, one had four 
hospital admissions and the other had seven admissions. The 
most common reason for admission during the study was 
clinical relapse (n = 47 [14.0%]), followed by psychiatric 
condition other than schizophrenia (n = 6 [1.8%]), medical 
condition (n = 5 [1.5%]), and other reasons (n = 4 [1.2%]). 
In terms of the use of other resources, the frequency of out-
patient visits to any physician, including psychiatrists, was 
lower during the study than during the 12 months before 
study entry. Fewer patients had eleven or more outpatient 
visits during the study (Month 3: n = 23 [6.2%]; Month 12: 
n = 52 [15.8%]) than before study entry (n = 177 [48.0%]), 
whereas more patients had one to ten outpatient visits during 
the study (Month 3: n = 317 [85.7%]; Month 12: n = 265 
[80.3%]) than before study entry (n = 179 [48.5%]). Less than 
10% of patients had visited an emergency room or an equiva-
lent facility (overnight stay) for psychiatric illness during the 
study, compared with about 45% of patients during the 
12 months before study entry. The proportions of patients 
who had an outpatient visit to physicians other than psychia-
trists, days in partial care, or an emergency room or equiva-
lent facility visit (overnight stay) for nonpsychiatric illness 
during the study was less than those during the 12 months 
before study entry.
Discussion
This is the first study to assess all cause treatment discontinu-
ation among outpatients with schizophrenia who were per-
ceived by their physicians to be at risk of nonadherence to 
their antipsychotic medication regimen. Conducted in usual 
care settings using a prospective observational design, 
patients switched antipsychotics at study entry and most were 
switched to oral rather than depot antipsychotics. The primary 
analysis indicated that during the study, few patients (24.4%) 
switched, augmented, or discontinued their antipsychotic 
medication prescribed at study entry. In addition, patients’ 
clinical and functional illness status improved significantly 
and rates of psychiatric hospitalization and emergency 
Table 3 Antipsychotic medication use patterns for all cause treatment discontinuation 
Switch, augmentation, 
or discontinuation, n (%)
Switch or augmentation 
only, n (%)
Discontinuation 
only, n (%)
Overall (n = 406) 99 (24.4) 93 (22.9) 6 (1.5)
Oral (n = 363) 91 (25.1) 85 (23.4) 6 (1.7)
First-generation (n = 38) 15 (39.5) 15 (39.5) 0 (0.0)
second-generation (n = 325) 76 (23.4) 70 (21.5) 6 (1.9)
Depot (n = 43) 8 (18.6) 8 (18.6) 0 (0.0)
First-generation (n = 21) 3 (14.3) 3 (14.3) 0 (0.0)
second-generation (n = 22) 5 (22.7) 5 (23.4) 0 (0.0)
Table 4 change in illness severity, attitude to antipsychotic medication, and quality of life scores
Score Study entry Month 12 
n Mean (SD) n Mean (SD) LS mean change (95% CI) Pa
cgi-sb 343 4.18 (0.97) 291 3.23 (1.08) -1.04 (-1.24, -0.84) ,0.001
DAi-10b 334 2.70 (5.37)  289  4.91 (5.24)  2.01 (1.36, 2.66)  ,0.001 
EQ-5Db
health state 337 56.4 (24.8) 291 66.3 (26.0) 12.64 (7.66, 17.62) ,0.001
Utilityf 324 0.62 (0.30) 277 0.77 (0.25) 0.16 (0.10, 0.23) ,0.001
SF-12c
Mental health 391 35.2 (10.9) 332 41.5 (11.4) 7.09 (5.11, 9.06) ,0.001
Physical component 391 44.2 (9.20) 332 47.4 (8.97) 4.52 (2.88, 6.15) ,0.001
Notes: achange in score from study entry to Month 12 (mixed-effect model for repeated measures analysis for cgi-s and sF-12 scores; analysis of covariance for eQ-5D 
scores); bExcluded patients who started treatment more than 7 days before their first study visit (patients eligible for assessment, n = 343); cexcluded patients who started 
treatment more than 28 days before their first study visit (patients eligible for assessment, n = 392). 
Abbreviations: CGI-S, Clinical Global Impressions of Severity; CI, confidence interval; DAI-10, 10-item Drug Attitude Inventory; EQ-5D, European Quality of life instrument; 
Ls, least square; nc, not calculated; sD, standard deviation; sF-12, 12-item short Form health survey.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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  psychiatric service use were low during the study. Most 
patients considered themselves to be adherent to their medi-
cation at study entry, and this favorable self-perception 
increased during this 1-year study, showing a discrepancy 
between the physicians’ perceptions of the patients’ risk of 
nonadherence and the patient’s assessment of their own 
adherence behaviors.
That few patients switched, augmented, or discontinued 
the antipsychotic medication prescribed at study entry was 
somewhat surprising given that the physicians considered 
these patients to be at risk of nonadherence. Even when study 
discontinuation was included, more than half of the patient 
group (59.4%) had continued to take their initial therapy for 
at least one year. However, it is difficult to compare the cur-
rent findings with previous research as most previous natu-
ralistic, observational studies in this field have shown wide 
variations in all cause treatment discontinuation rates, 
depending on the specific antipsychotic prescribed.14,17,18,28 
Although patients in previous studies were not assessed for 
their risk of nonadherence at study entry, the proportion of 
patients who completed one year of treatment without chang-
ing their antipsychotic medication varied from 22.7% to 
71.6% in one large naturalistic United States (US) study,17 
53.7% to 69.1% in a prospective, observational Canadian 
study,28 17.8% to 44.4% in the Intercontinental Schizophrenia 
Outpatient Health Outcomes (IC-SOHO) study,18 and 20.5% 
to 48.6% in the European SOHO study.14
The low treatment discontinuation rate found in the cur-
rent study may reflect the fact that more than 75% of patients 
were switched to a second-generation oral antipsychotic at 
study entry. This finding possibly reflects physicians’ percep-
tions that these antipsychotics may provide better efficacy 
for patients with insufficient response.29 Although this study 
was not designed to assess treatment discontinuation rates 
for the individual antipsychotics, the 1-year treatment dis-
continuation rates in the current study are somewhat similar 
to those reported for olanzapine-treated patients in other 
naturalistic schizophrenia studies, eg, 24.4% versus 17.8% 
for IC-SOHO,18 and 23.0% for European SOHO,14 and when 
study discontinuation was considered, 40.6% versus 43.5% 
for the large naturalistic US study.17 However, in the current 
study, patients were switched to a variety of antipsychotics 
at study entry, in   keeping with clinical practice, and only 
22.9% of patients were switched to olanzapine thus rendering 
this potential explanation incomplete.
Although previous findings suggest that patients are less 
likely to discontinue depot antipsychotics than oral 
antipsychotics,30,31 it is unlikely that the prescription of depot 
antipsychotics at study entry influenced the treatment 
discontinuation rate in the current study. Few patients were 
switched to depot antipsychotics at study entry, despite being 
considered at risk of nonadherence. A number of factors may 
have influenced this result, including patient acceptance of,32 
and preference for33 depot formulations; the physician’s 
attitude towards depot,34 judgment of whether depot will be 
noticeably more effective than oral formulations,35 and expe-
riences with prescribing depot; and the availability, cost, and 
resources needed to administer depot in each of the study 
countries and regions.36,37
The discrepancy between the physicians’ perceptions of 
the patients’ risk of nonadherence and the patients’ assess-
ment of their own adherence is of particular interest. Despite 
classifying their patients as being at risk of nonadherence, 
physicians may have elected for study inclusion those patients 
whose attitude toward taking antipsychotics was more posi-
tive (mean DAI-10 score at study entry was slightly positive) 
but whose behavior (whether they take the medication 
or not),38 or antipsychotic medication regimen,2,3 made them 
susceptible to nonadherence or treatment discontinuation. 
Few patients in the current study were considered at risk of 
nonadherence because of poor insight or a negative attitude 
to medication. Rather, most patients who were enrolled were 
considered at risk because of an inadequate response or 
intolerance to the primary antipsychotic medication. Most 
patients considered themselves to be adherent at study entry 
and this favorable self-perception increased during the study, 
possibly owing to selective attrition. Previous research has 
shown that patients tend to overestimate their medication 
adherence when reporting adherence.39 Given that patient-
reported adherence was measured using a subjective assess-
ment scale, the patients’ favorable self-perception of 
adherence in the current study may reflect their views and 
attitudes about adherence rather than actual adherence to 
their prescribed medication regimen.40 As patient adherence 
was not monitored by objective measures, the extent to which 
patients adhered to their medication regimen is not known, 
and even though the treatment discontinuation rate was low, 
patients may not have taken their medication as prescribed 
or were partially adherent to their antipsychotic medication 
regimen.41,42
Current findings need to be evaluated in the context of 
the study limitations. First, this study may not have enrolled 
those patients most susceptible to nonadherence, which in 
turn, may have contributed to the observed low treatment 
discontinuation rate. The proportion of patients (38.0%) 
considered to be at risk of nonadherence that refused to Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
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participate in the current study suggests that enrolled   
patients were not a representative sample of the spectrum of 
nonadherent patients.   Moreover, few patients were prescribed 
depot antipsychotics at study entry, which tends to be 
reserved for patients with a clear history of, or high risk for, 
  nonadherence.11 Another possibility is that patients who were 
more engaged in their outpatient treatment may have been 
approached by physicians for enrollment in this study, as 
outpatients who are nonadherent to medication also tend to 
be nonadherent to their outpatient therapy program.43 
  Different sampling methods may need to be considered in 
future studies of this topic. Second, the five criteria used to 
identify risk of nonadherence in the current study may have 
resulted in physicians overlooking patients who were at risk 
because of other known predictors of nonadherence, such as 
recent illicit drug and alcohol abuse.19,20 Lastly, the general-
ization of the current findings to individual populations is 
challenging because of the distinct variability in antipsychotic 
prescribing practices across the study countries and regions, 
and differences in treatment discontinuation rates across 
countries and regions.44
Conclusion
In this 1-year naturalistic study, few patients discontinued 
their treatment for any reason even though these patients 
were considered at risk of nonadherence by their physicians. 
This finding was accompanied by significant improvements 
in the patients’ clinical and functional status. Current results 
suggest the need for further research of patients with schizo-
phrenia who are considered to be nonadherent to their antip-
sychotic medications and the need to understand the factors 
that may drive the marked discrepancy between the physi-
cians’ perception of their patients’ adherence to the pre-
scribed medication and the patients’ assessment of their own 
adherence behaviors.
Acknowledgments
This study was sponsored by Eli Lilly and Company. 
Eli Lilly was involved in the study design, data collection, 
data analysis, and preparation of the manuscript. In compli-
ance with the Uniform Requirements for Manuscripts, 
established by the International Committee of Medical 
Journal Editors, the sponsor of this study did not impose 
any impediment, directly or indirectly, on the publication 
of the study’s results. The authors acknowledge statistical 
analysis assistance provided by George Zhao. The authors 
acknowledge the independent medical writing assistance 
provided by Julie Monk and Serina Stretton of ProScribe 
Medical Communications (www.proscribe.com.au), funded 
from an unrestricted financial grant from Eli Lilly Australia. 
ProScribe’s services complied with international guidelines 
for Good Publication Practice. The authors acknowledge 
Renee Granger for editorial support.
Disclosure
K Kelin, AJM Brnabic, J Karagianis, W Montgomery, W Ye, 
and H Ascher-Svanum are employees of Eli Lilly and 
  Company.  R  Newton  has  received  honoraria  from 
  AstraZeneca, Eli Lilly and Company, Janssen-Cilag Pty 
Limited, and Lundbeck Australia Pty Ltd. TJR Lambert has 
been on advisory boards and consulted for, and received 
honoraria and/or educational grants from, Eli Lilly and 
Company,  Janssen-Cilag  Pty  Limited,  Pfizer  Inc, 
  AstraZeneca, and Hospira, Inc. AJM Brnabic, J Karagianis, 
W Montgomery, and W Ye are shareholders in Eli Lilly and 
Company. K-P Chen, L Don and RI Escamilla have no 
conflicts of interest to disclose.
References
  1.  Canadian Psychiatric Association. Clinical practice guidelines.   Treatment 
of schizophrenia. Can J Psychiatry. 2005;50(Suppl 1):7–57.
  2.  Haro JM, Novick D, Suarez D, Roca M. Antipsychotic treatment 
  discontinuation in previously untreated patients with schizophrenia: 
36-month results from the SOHO study. J Psychiatr Res. 2009;43: 
265–273.
  3.  Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsy-
chotic drugs in patients with chronic schizophrenia. N Engl J Med. 
2005;353:1209–1223.
  4.  Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify 
poorly adherent patients with schizophrenia at increased risk for 
  admission. Medical Care. 2002;40:630–639.
  5.  Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and 
risk of rehospitalization among California Medicaid patients with 
schizophrenia. Psychiatr Serv. 2004;55:886–891.
  6.  Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to 
assess the relationship of medication adherence with hospitalization 
and costs. Psychiatr Serv. 2001;52:805–811.
  7.  Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of 
schizophrenic patients is driven by poor symptom response: a pooled 
post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 
2005;3:21.
  8.  Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. 
Time to discontinuation of atypical versus typical antipsychotics in the 
naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6:8.
  9.  Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antip-
sychotic treatment discontinuation for any cause is associated with 
better functional outcomes for patients with schizophrenia, schizo-
phreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 
2007;68:1163–1171.
  10.  Corrigan PW, Liberman RP, Engel JD. From noncompliance to collabo-
ration in the treatment of schizophrenia. Hosp Community Psychiatry. 
1990;41:1203–1211.
  11.  Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antip-
sychotic medication impacts the course of illness in patients with 
schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 
2009;11:147–154.Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, open 
access journal focusing on the growing importance of patient preference 
and adherence throughout the therapeutic continuum. Patient satisfaction, 
acceptability, quality of life, compliance, persistence and their role in 
developing new therapeutic modalities and compounds to optimize   
clinical outcomes for existing disease states are major areas of interest. 
This journal has been accepted for indexing on PubMed Central. The 
manuscript management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
222
Kelin et al
  12.  Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of 
Mental Health Clinical Antipsychotic Trials of Intervention Effective-
ness (CATIE) project: schizophrenia trial design and protocol 
  development. Schizophr Bull. 2003;29:15–31.
  13.  Chen L, McCombs JS, Park J. Duration of antipsychotic drug therapy 
in real-world practice: a comparison with CATIE trial results. Value 
Health. 2008;11:487–496.
  14.  Haro JM, Novick D, Belger M, Jones PB. Antipsychotic type and cor-
relates of antipsychotic treatment discontinuation in the outpatient 
treatment of schizophrenia. Eur Psychiatry. 2006;21:41–47.
  15.  Kilzieh N, Todd-Stenberg JA, Kennedy A, Wood AE, Tapp AM. Time 
to discontinuation and self-discontinuation of olanzapine and risperi-
done in patients with schizophrenia in a naturalistic outpatient setting. 
J Clin Psychopharmacol. 2008;28:74–77.
  16.  Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of 
discontinuation of atypical antipsychotic agents in the treatment of 
schizophrenia. Schizophr Res. 2008;98:8–15.
  17.  Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X. 
Adherence and persistence to typical and atypical antipsychotics in the 
naturalistic treatment of patients with schizophrenia. Patient Prefer 
Adherence. 2008;2:67–77.
  18.  Dossenbach M, Arango-Dávila C, Silva Ibarra H, et al. Response and 
relapse in patients with schizophrenia treated with olanzapine, risperi-
done, quetiapine, or haloperidol: 12-month follow-up of the Intercon-
tinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. 
J Clin Psychiatry. 2005;66:1021–1030.
  19.  Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective 
study of risk factors for nonadherence with antipsychotic medication in 
the treatment of schizophrenia. J Clin Psychiatry. 2006;67: 1114–1123.
  20.  Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV . Prevalence 
of and risk factors for medication nonadherence in patients with schizo-
phrenia: a comprehensive review of recent literature. J Clin Psychiatry. 
2002;63:892–909.
  21.  Kelin K, Brnabic AJM, Newton R, et al. Baseline characteristics and 
initial treatment decisions for patients with schizophrenia at risk of 
treatment nonadherence. Pat Pref Adherence. 2010;4:301–311.
  22.  American Psychiatric Association (APA). Diagnostic and statistical 
manual of mental disorders (DSM-IV). Washington DC: American 
Psychiatric Association; 1994.
  23.  Guy W. ECDEU assessment manual for psychopharmacology. 
  Rockville, MD: US Department of Health, Education, and Welfare, 
Public Health Service, Alcohol, Drug Abuse, and Mental Health 
  Administration, National Institute of Mental Health, Psychopharmacology 
Research Branch, Division of Extramural Research Programs; 1976.
  24.  Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of 
drug compliance in schizophrenics: reliability and discriminative 
  validity. Psychol Med. 1983;13:177–183.
  25.  The EuroQol Group: EuroQol – a new facility for the measurement of 
health-related quality of life. Health Policy. 1990;16:199–208.
  26.  Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey 
(SF-36). I. Conceptual framework and item selection. Med Care. 
1992;30:473–483.
  27.  Dolan P. Modeling valuations for EuroQol health states. Med Care. 
1997;35:1095–1108.
  28.  Karagianis J, Williams R, Davis L, et al. Antipsychotic switching: 
results from a one-year prospective, observational study of patients 
with schizophrenia. Curr Med Res Opin. 2009;25:2121–2132.
  29.  Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics 
and schizophrenia: a review on efficacy and side effects. Curr Med 
Chem. 2004;11:343–358.
  30.  Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsy-
chotic treatments in a nationwide cohort of patients in community care 
after first hospitalisation due to schizophrenia and schizoaffective 
disorder: observational follow-up study. BMJ. 2006;333:224.
  31.  Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. 
Time to discontinuation of depot and oral first-generation antipsychotics 
in the usual care of schizophrenia. Psychiatr Serv. 2008;59:315–317.
  32.  Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients 
towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007; 
22:275–282.
  33.  Patel MX, de Zoysa N, Bernadt M, David AS. A cross-sectional study 
of patients’ perspectives on adherence to antipsychotic medication: 
depot versus oral. J Clin Psychiatry. 2008;69:1548–1556.
  34.  Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists 
toward antipsychotic depot medication. J Clin Psychiatry. 2006;67: 
1948–1953.
  35.  Hamann J, Mendel R, Heres S, Leucht S, Kissling W. How much more 
effective do depot antipsychotics have to be compared to oral antipsy-
chotics before they are prescribed? Eur Neuropsychopharmacol. 2010; 
20:276–279.
  36.  Chong MY, Tan CH, Fujii S, et al. Antipsychotic drug prescription for 
schizophrenia in East Asia: rationale for change. Psychiatry Clin 
  Neurosci. 2004;58:61–67.
  37.  Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of 
schizophrenia in Taiwan: model comparison of long-acting risperidone 
versus olanzapine versus depot haloperidol based on estimated costs. 
Psychiatry Clin Neurosci. 2005;59:385–394.
  38.  Weiden PJ. Understanding and addressing adherence issues in schizo-
phrenia: from theory to practice. J Clin Psychiatry. 2007;68(Suppl 14): 
14–19.
  39.  Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adher-
ence to oral antipsychotics: a review of the literature. Schizophr Bull. 
2006;32:724–742.
  40.  Barbui C, Kikkert M, Mazzi MA, et al. Comparison of patient and clini-
cian perspectives in the assessment of antipsychotic medication 
  adherence. Psychopathology. 2009;42:311–317.
  41.  Cooper D, Moisan J, Grégoire JP. Adherence to atypical antipsychotic 
treatment among newly treated patients: a population-based study in 
schizophrenia. J Clin Psychiatry. 2007;68:818–825.
  42.  Byerly M, Fisher R, Whatley K, et al. A comparison of electronic 
monitoring vs clinician rating of antipsychotic adherence in outpatients 
with schizophrenia. Psychiatry Res. 2005;133:129–133.
  43.  Nosé M, Barbui C, Tansella M. How often do patients with psychosis 
fail to adhere to treatment programmes? A systematic review. Psychol 
Med. 2003;33:1149–1160.
  44.  Bitter I, Treuer T, Dyachkova Y, Martenyi F, McBride M, Ungvari GS. 
Antipsychotic prescription patterns in outpatient settings: 24-month 
results from the Intercontinental Schizophrenia Outpatient Health Out-
comes (IC-SOHO) study. Eur Neuropsychopharmacol. 2008;18: 
170–180.